Last reviewed · How we verify
NCT07076979
Development and Validation of Metabolic Biomarkers for Early Diagnosis, Prognosis, and Recurrence of Gastric Cancer：MetBio-GC
trial in Gastric Cancer in 250 participants. Currently enrolling.
1 July 2028
Quick facts
| Lead sponsor | Shanghai Minimally Invasive Surgery Center |
|---|---|
| Status | Recruiting now |
| Study type | OBSERVATIONAL |
| Enrollment | 250 |
| Start date | 15 June 2025 |
| Primary completion | 1 July 2028 |
| Estimated completion | 1 July 2030 |
| Sites | 1 location across China |
Conditions studied
- Gastric Cancer — all drugs for Gastric Cancer →
Sponsor
Shanghai Minimally Invasive Surgery Center — full company profile →
Who can join
18 and older, any sex, with Gastric Cancer. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This prospective clinical observational study aims to construct a metabolite database specifically for gastric cancer patients using metabolomics technology. It seeks to develop and validate metabolic biomarkers for early diagnosis, prognosis, and prediction of recurrence and metastasis in gastric cancer, thereby a establishing safe, convenient, and highly sensitive method for early screening and prognostic prediction.
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
Blood-Based Surveillance Biomarkers for Gastroesophageal Cancers.
Dadgar N, Anees M, Sherry C, Park HY, et al · · 2025 · cited 2× · PMID 41228346 · DOI 10.3390/cancers17213552
Verify or expand the search:
- PubMed search for NCT07076979
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Gastric Cancer
Currently open trials in the same condition.
- NCT07525765 — AI-assisted Decision-making of Reoperation for Postoperative Bleeding of Gastric Cancer · recruiting
- NCT07464470 — Comparison of Molecular-Genetic Concordance of the Primary Tumor and Brain Metastases of Gastroesophageal Cancers · recruiting
- NCT07432633 — [18F]FPyQCP PET Imaging of Fibroblast Activation Protein in Selected Oncology Indications · Phase 1, PHASE2 · recruiting
- NCT07431281 — Sonesitatug Vedotin in Combination With Capecitabine With or Without Rilvegostomig in Participants With Advanced or Meta · Phase 3 · recruiting
- NCT07448493 — Local Treatment Strategies for Brain Metastases of Gastric and Esophageal Cancer · active not recruiting
Other Shanghai Minimally Invasive Surgery Center trials
Trials by the same sponsor.
- NCT07068529 — Development and Validation of Metabolic Biomarkers for Early Diagnosis, Prognosis, and Recurrence of Colorectal Cancer：M · recruiting
- NCT06746298 — A Prospective Study of Expression Profiling-based Assessment of the Efficacy of Neoadjuvant Therapy for Rectal Cancer · not yet recruiting
- NCT04620473 — Anlotinib Hydrochloride Combined With Capeox in the Neoadjuvant Treatment of Locally Advanced Rectal Cancer · Phase 2 · withdrawn
- NCT05495048 — Transvaginal NOSES Versus Conventional Laparoscopic Surgery for Right Hemicolectomy · NA · recruiting
- NCT05352165 — The Clinical Efficacy of Drug Sensitive Neoadjuvant Chemotherapy Based on Organoid Versus Traditional Neoadjuvant Chemot · NA · unknown
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT07076979 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Shanghai Minimally Invasive Surgery Center
- Last refreshed: 22 July 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07076979.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing